Alex Kalomparis, Gilead senior VP of public affairs
September 19, 2023 11:13 AM EDTUpdated 02:45 PM
Pharma
Marketing

Q&A: Gilead pub­lic af­fairs chief on new strat­e­gy, Tik­Tok, and why the com­pa­ny won’t ‘keep do­ing things the same way’ 

Beth Snyder Bulik

Senior Editor

Af­ter years of qui­et fo­cus on HIV and vi­rol­o­gy and sto­ic re­spons­es to flare-ups of at­ten­tion over its pric­ing de­ci­sions, the new Gilead Sci­ences is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times